German Merck plans for new US Healthcare headquarters

15 November 2023

German life sciences and pharma company Merck KGaA (MRK: DE), which operates its Healthcare business as EMD Serono in the USA and Canada, yesterday announced that it plans to move its US Healthcare headquarters, currently located in Rockland, Massachusetts, to Boston’s Seaport district.

“The US market is critical to our continued success as a global specialty innovator. Today we deliver important therapeutic options to more than 150,000 oncology, multiple sclerosis (MS) and fertility patients in the US,” said Chris Round, president of EMD Serono.”This move serves as an important milestone in our journey to bring further innovation to address high unmet medical needs in areas where patients rely on us. Our vibrant new office setting in the Seaport district will bring EMD Serono into the center of the globally leading healthcare innovation hub to support our future growth,” he added.

Product launch plans

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK